Tecan Group AG (TECN.SW) stock: key figures, P/E, revenue and dividend

Health Care · Switzerland · ISIN CH0012100191

Price
251.20 CHF
Market cap
3.18 bn CHF
P/E (2025)
–
P/S (2025)
3.61
Dividend yield
1.19 %
Net margin
-12.47 %
Return on equity (ROE)
-9.55 %
Return on assets (ROA)
-6.48 %

Tecan Group AG financials

Fiscal year20242025
Revenue934.00 m CHF882.00 m CHF
Gross profit320.00 m CHF280.00 m CHF
Operating income75.32 m CHF44.98 m CHF
EBIT75.00 m CHF25.00 m CHF
Net income67.00 m CHF-110.00 m CHF
Diluted EPS – continuing operations5.30 CHF-8.73 CHF

Full history since 1996, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Tecan Group AG

Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments: Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, sequencing reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution. It also provides PARAMIT, a contract design and manufacturing service. Tecan Group AG has a strategic collaboration with NVIDIA Corporation to develop AI-enabled platform for data-driven laboratories to help discoveries and lab productivity. The company was founded in 1980 and is headquartered in Männedorf, Switzerland.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.